Clinical Trial Detail

NCT ID NCT02312557
Title Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

prostate cancer

Therapies

Enzalutamide + Pembrolizumab

Age Groups: adult

No variant requirements are available.